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been nauseous and vomiting at home and had been 
confused and drowsy. He was, however, able to call for 
help after two days. He reported no abdominal pain but 
was tremulous and dehydrated and had noticed that he 
was no longer passing urine. His serum creatinine at 
presentation was 641 μmol/L compared to 69 μmol/L 
three months earlier. He was admitted and rehydrated 
over the next 72 hours but remained anuric and was 
therefore referred to our hospital for evaluation and 
further treatment. On admission to our unit, he was 
oedematous and in pulmonary oedema with respiratory 
distress. The serum creatinine was now 1264 μmol/L and 
he was started on haemodialysis three times per week. 
Despite beginning to pass normal volumes of urine 
within a week, he remained dialysis-dependent at six 
weeks. A renal biopsy was performed six weeks after 
admission, to exclude an associated interstitial nephritis. 
The biopsy confirmed acute tubular necrosis (ATN) with 
normal glomeruli and only mild interstitial changes, but 
also demonstrated a brownish-green pigment present 
in the cytoplasm of some tubular epithelial cells. The 
 
AbstrAct
Nephrotoxicity due to chronic use of tenofovir disoproxil fumarate (TDF) is well described, but very little is known 
or published about the effects of acute toxicity or the clinical management of this condition.  We present here a case 
of acute and irreversible renal failure that followed an intentional overdose of fixed dose combination antiretroviral 
therapy containing efavirenz, TDF and emtricitabine.  The renal histology findings are discussed and a rationale for 
the use of emergency haemodialysis in the management of TDF overdose is presented. 
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INtrODUctION
Nephrotoxicity due to chronic use of tenofovir disoproxil 
fumarate (TDF) is well-described in the literature; risk 
factors for toxicity include older age, low body weight 
and CD4 count, concomitant use of nephrotoxic agents, 
male sex, hepatitis C co-infection and advanced HIV 
disease [1]. Very little is known or published about the 
effects of acute toxicity or the clinical management of this 
condition. We present here a case of intentional 
overdose resulting in TDF toxicity. 
cAsE PrEsENtAtION
A 42-year-old HIV-positive white male presented to a 
secondary hospital in February 2017, three days after 
attempting suicide by overdosing on his fixed-dose com-
bination antiretroviral tablets (Odimune; Cipla) con-
taining TDF 300 mg, emtricitabine 200 mg (FTC) and 
efavirenz 600 mg (EFV). He had been taking TDF/FTC/
EFV treatment daily since starting HIV treatment in 
2014 and had a supressed viral load. He reported 
ingesting 90 tablets, comprising 54 g EFV, 18 g FTC and 
27 g TDF (or 450 mg/kg). Since the overdose, he had 
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pigment was associated with indentations and pyknosis of 
the nuclei that appeared to precede cell necrosis and loss 
of nuclear detail. In addition, patchy areas of anuclear 
proximal tubules containing pigment were also present. 
The pigment did not stain with periodic acid–Shiff, 
Masson’s trichrome or Perl’s Prussian blue stains (Figure 
1a–c). Electron microscopy of the tubular epithelium 
revealed degenerate epithelial cells and reduced numbers 
of mitochondria. In addition, there were areas of osmio-
philic degenerate material which were thought to repre-
sent degenerate mitochondria and correlated with the 
deposits observed on light microscopy (Figure 2a–d). 
Unfortunately, our patient did not recover sufficient renal 
function and was therefore transitioned onto continuous 
ambulatory peritoneal dialysis on which he is doing well. 
The serum creatinine six months after the initial overdose 
was 473 μmol/L.
DIscUssION
Toxicity with chronic use of TDF results in proximal tubular 
dysfunction and can manifest as a full or partial Fanconi 
syndrome and/or progressive renal dysfunction. The pro-
posed mechanism is due to drug accumulation in proximal 
tubular cells with resultant mitochondrial toxicity through 
inhibition of mitochondrial gamma polymerase and con-
sequent oxidative stress and impaired cellular protective 
responses. Histologically, apart from the usual non-specific 
manifestations of acute tubular necrosis, this may be asso-
ciated with pigmented inclusions in proximal tubular cells 
seen on haematoxylin and eosin staining on light micro-
scopy and seen as abnormal and giant mitochondria on 
electron microscopy [2]. Genetic polymorphisms in proxi-
mal tubular transporters are also thought to contribute to 
the risk of intracellular accumulation in individuals [1,3]. 
The mechanism of acute toxicity is unclear, although it is 
conceivable that it would be similar to that of chronic 
toxicity described above. We could find only one report 
describing acute toxicology in rats, which defined the 
animal toxic dose as more than 30 mg/kg. Interestingly, 
pigment accumulation in the proximal tubules of all rats 
exposed to TDF was noted at 43 weeks after dosing [4]. 
Little is known about acute toxicity due to overdose in 
humans and the only information available is limited to a 
handful of case reports. Havenith et al. [5] have recently 
reported a case where acute kidney injury complicated 
EFV/FTC/TDF (Atripla, MSD) overdose, with partial recov-
ery of renal function; the ingested TDF dose was 21 g. In 
their case, dialysis was initiated on day nine after initial 
expectant management and was required for a total of 
six weeks before partial renal recovery to an estimated 
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Figure 1.  (a) Renal cortex with brownish-green pigment 
present in the cytoplasm of some tubular epithelial cells 
(haematoxylin and eosin stain, original magnification x400). 
(b) Highlighted area, from fig 1(a), showing pigment with loss 
of nuclear detail. (c) The pigment indents the nucleus and is 
negative on a periodic acid–Schiff stain (periodic acid-Schiff 
stain, original magnification x400).
a)
b)
c)
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glomerular filtration rate of 35 mL/min. In their report, the 
authors justify why earlier use of haemodialysis would be 
expected to result in a rapid reduction of plasma TDF 
levels: TDF is a prodrug of the acyclic nucleotide reverse 
transcriptase inhibitor tenofovir and is eliminated exclu-
sively in the urine with no extra-renal route of elimination. 
Peak serum levels (Cmax) are achieved within 0.5–4 hours 
after dosing in healthy volunteers. High-flux haemodialysis, 
started at Cmax and continued for 4 hours, removes TDF 
with a clearance rate of 134 mL/min and an extraction 
ratio of 54%, resulting in the removal of approximately 50% 
of the bioavailable ingested dose. Serum levels rebound 
somewhat after discontinuation of dialysis, reflecting redis-
tribution from the tissues [6]. Therefore, early initiation of 
high-intensity and prolonged or repeated haemodialysis 
would be expected to markedly reduce plasma levels of 
TDF in patients presenting with an overdose, although it is 
uncertain whether this would translate into clinical benefit 
and prevention of AKI.  
Lee et al. have also recently described a case of dolutegravir, 
FTC and TDF overdose, which was associated with mild 
and reversible AKI and where dialysis was not performed. 
However, as Havenith et al. point out, the total ingested 
dose was far lower at 4.9 g [7]. In our case, the ingested 
dose of 27 g is much higher, and similar to that reported 
by Havenith et al. where there was only partial recovery 
of renal function. 
The renal histology in our case demonstrated severe proxi-
mal tubular necrosis, which would be in keeping with a 
toxic insult to the kidney. Proximal tubular cells demon-
strated cellular swelling and the presence of a green-brown 
pigment in cells which were anuclear. This is notable given 
the description of pigmented deposits being present in 
animal toxicology studies of tenofovir [4]. Electron micro-
scopy of the tubular epithelium in this case confirmed a 
toxic acute tubular necrosis with a decrease in the number 
of normal mitochondria and a large amount of material 
thought to represent degenerate mitochondria. The mito-
chondria were not found to be dysmorphic as in prior 
reports [2], but this may be because of the acute nature of 
the insult in this case compared to the chronic toxicity 
previously described. Our patient had no clinical evidence 
to suggest chronic toxicity given that he had a normal 
baseline serum creatinine just a few months prior to pre-
sentation. No urine testing had been done prior to his 
overdose and since he was anuric at presentation, it was 
not possible to assess for other markers of tubular toxicity.
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Figure 2.  Electron microscopy of tubular epithelium. (a) Degenerate tubular epithelial cell (solid white arrow) and loss of the 
normal brush border in keeping with acute tubular necrosis (original magnification x6000). (b) Tubular epithelial cells with reduced 
number of mitochondria (original magnification x8000). (c) High-power view of tubular epithelial cells with normal (arrowhead) and 
degenerate (chevron) mitochondria (original magnification x12000). (d) High-power view of tubular epithelial cells with degenerate 
mitochondria (chevron) and tubular basement epithelium (diamond) (original magnification x10000).
a)
c)
b)
d)
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It is not known whether earlier haemodialysis could have 
ameliorated the severe renal injury in our patient, although 
as described above, it is possible to rapidly lower serum 
levels of TDF with appropriate haemodialysis. What is also 
not clear is why there have been so few reports of renal 
injury following antiretroviral therapy overdose and we 
speculate that factors such as genetic susceptibility to TDF 
accumulation could also play a role in the genesis of tubular 
injury in acute exposure as for those in chronic exposure. 
Other factors such as chronic use as well as accompany- 
ing vomiting and hypovolaemia, as in this patient, could 
also increase individual susceptibility to renal injury.
Tenofovir alafenamide (TAF) is a prodrug of tenofovir, 
which is metabolised intracellularly to its active metabo- 
lite, tenofovir diphosphate. Compared to TDF, this allows 
for lower dosing, lower plasma tenofovir concentrations 
and lower toxicity, while retaining similar antiviral efficacy 
[8]. Replacement of TDF by TAF would, one hopes, see a 
reduction in the risk of developing renal disease. Presumed 
TAF-related nephrotoxicity has, however, been reported in 
a patient with significant renal co-morbidity, so although 
TAF is generally associated with improved renal outcomes, 
clinicians should remain vigilant when using TAF in high risk 
patients [9]. 
cONclUsIONs
In summary, we have presented a case of acute and irre-
versible renal failure following intentional overdose of 
TDF/FTC/EFV combination antiretroviral tablets. Clinicians 
need to be aware of the potential for severe AKI in such 
instances and of the role of emergency haemodialysis in 
lowering serum TDF levels. It is uncertain, though, whether 
this strategy will ameliorate or prevent associated AKI and 
this requires further study. 
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